Pharmaceuticals, Biotechnology and Life Sciences
Biocartis Group has posted net income loss of €50.2 million for 2016, which is loss increase compared to last years €39.7 million net loss.
PureTech Health has named Bharatt Chowrira as its President and Chief of Business and Strategyto work with the Chief Executive on strategy, corporate and business development, and value realisation across PureTech Health’s pipeline, the company said in its annoucement on Thursday.
Board of Directors has appointed its former executive vice preisdent Claus Bo Svendsen, as Chief Executive Officer, as it plans to pursue important objectives related to the the Settlement and License Agreement with Biogen.
Novartis is making progress in its bid to catch rivals developing drugs that harness the immune system to fight cancer, one of its top research scientists and latest recruit from Harvard University told Reuters in an interview
Novo Nordisk’s executive vice president, head of North America Operations and president of Novo Nordisk Inc. Jakob Riis has resigned from the company, and will be replaced by senior vice president for Market Access, Doug Langa.
A research group from University College London’s (UCL’s) Centre for Rheumatology has been awarded a £3.5m grant from the Medical Research Council (MRC) to continue developing of a new treatment for anti-phospholipid syndrome (APS) which uses Abzena’s proprietary conjugation technology.
Euronext-listed Genticel and a privately-held Swiss GenKyoTex biopharmaceutical companies, will come together to become Genkyotex, a listed Franco-Swiss company whose focus will be develping a a pipeline of NOX inhibitors, a new therapeutic class in fibrosis and inflammatory pain.
According to Deloitte’s 2017 Global Health Care Sector Outlook the challenges of providing and funding healthcare around the world are likely to continue this year due to the rising demands and associated spending of the aging population, the growing prevalence of chronic diseases and comorbidities, the development of costly clinical innovations, increasing patient expectations, and continued economic turbulence.
UBM EMEA announces the rebranding and relocation of CPhI Istanbul into CPhI Middle East & Africa, which will open next year (3-5 September 2018) at ADNEC Centre, Abu Dhabi, United Arab Emirates (UAE).
ASIT biotech, a Belgian clinical-stage biopharmaceutical company could soon market its gp-ASIT+ grass pollen product, as it showed positive results in Phase III clinical trial in grass pollen rhinitis.